{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:30:44Z","timestamp":1793302244781,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,8,25]],"date-time":"2016-08-25T00:00:00Z","timestamp":1472083200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s00198-016-3729-x","type":"journal-article","created":{"date-parts":[[2016,8,25]],"date-time":"2016-08-25T05:39:18Z","timestamp":1472103558000},"page":"339-346","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Serum creatine kinase isoenzymes in children with osteogenesis imperfecta"],"prefix":"10.1007","volume":"28","author":[{"given":"P.","family":"D\u2019Eufemia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Finocchiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Zambrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Lodato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Celli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Finocchiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Persiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Turchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Celli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,25]]},"reference":[{"key":"3729_CR1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1042\/bj2810021","volume":"281","author":"T Wallimann","year":"1992","unstructured":"Wallimann T, Wyss M, Brdiczka D, Nicolay K, Eppenberger HM (1992) Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis. Biochem J 281:21\u201340","journal-title":"Biochem J"},{"key":"3729_CR2","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s00726-011-0877-3","volume":"40","author":"T Wallimann","year":"2011","unstructured":"Wallimann T, Tokarska-Schlattner U (2011) The creatine kinase system and pleiotropic effects of creatine. Amino Acids 40:1271\u20131296","journal-title":"Amino Acids"},{"key":"3729_CR3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S8756-3282(95)00152-2","volume":"17","author":"D Sakai","year":"1995","unstructured":"Sakai D, Tong HS, Minkin C (1995) Osteoclast molecular phenotyping by random cDNA sequencing. Bone 17:111\u2013119","journal-title":"Bone"},{"key":"3729_CR4","doi-asserted-by":"crossref","first-page":"36315","DOI":"10.1074\/jbc.M110.157743","volume":"285","author":"J Chen","year":"2010","unstructured":"Chen J, Sun Y, Mao X, Liu Q, Wu H, Chen Y (2010) RANKL up-regulates brain-type creatine kinase via poly (ADP-ribose) polymerase-1 during osteoclastogenesis. J Biol Chem 285:36315\u201336321","journal-title":"J Biol Chem"},{"key":"3729_CR5","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/nm.1860","volume":"14","author":"EJ Chang","year":"2008","unstructured":"Chang EJ, Ha J, Oerlemans F, Lee YL, Lee SW, Ryu J, Hj K, et al. (2008) Brain-type creatine kinase has a crucial role in osteoclast-mediated bone resorption. Nat Med 14:966\u2013972","journal-title":"Nat Med"},{"key":"3729_CR6","first-page":"1284","volume":"320","author":"T Yoneyama","year":"1989","unstructured":"Yoneyama T, Fowler HL, Pendleton JW, et al. (1989) Elevated levels of creatine kinase BB isoenzyme in three patients with adult osteopetrosis. N Engl J Med 320:1284\u20131285","journal-title":"N Engl J Med"},{"key":"3729_CR7","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/BF02556458","volume":"48","author":"J Gram","year":"1991","unstructured":"Gram J, Antonsen S, H\u00f8rder M, et al. (1991) Elevated serum level of creatine kinase BB in autosomal dominant osteopetrosis type II. Calcif Tissue Int 48:438\u2013439","journal-title":"Calcif Tissue Int"},{"key":"3729_CR8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1399-0004.1992.tb03134.x","volume":"42","author":"T Yoneyama","year":"1992","unstructured":"Yoneyama T, Fowler HL, Pendleton JW, et al. (1992) Elevated serum levels of creatine kinase bb in autosomal dominant osteopetrosis type II\u2014a family study. Clin Genet 42:39\u201342","journal-title":"Clin Genet"},{"key":"3729_CR9","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/jbmr.5650111010","volume":"11","author":"MP Whyte","year":"1996","unstructured":"Whyte MP, Chines A, Silva DP Jr, et al. (1996) Creatine kinase brain isoenzyme (BB-CK) presence in serum distinguishes osteopetrosis among the sclerosing bone disorder. J Bone Miner Res 11:1438\u20131443","journal-title":"J Bone Miner Res"},{"issue":"5","key":"3729_CR10","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1210\/jcem.87.5.8497","volume":"87","author":"SG Waguespack","year":"2002","unstructured":"Waguespack SG, Hui SL, White KE, et al. (2002) Measurement of tartrate-resistant acid phosphatase and the brain isoenzyme of creatine kinase accurately diagnoses type II autosomal dominant osteopetrosis but does not identify gene carriers. J Clin Endocrinol Metab 87(5):2212\u20132217","journal-title":"J Clin Endocrinol Metab"},{"key":"3729_CR11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJMoa023110","volume":"349","author":"MP Whyte","year":"2003","unstructured":"Whyte MP, Wenkert D, Clements KL, et al. (2003) Bisphosphonate-induced osteopetrosis. N Engl J Med 349:457\u2013463","journal-title":"N Engl J Med"},{"key":"3729_CR12","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1359\/jbmr.080511","volume":"23","author":"MP Whyte","year":"2008","unstructured":"Whyte MP, McAlister WH, Novack DV, et al. (2008) Bisphosphonate-induced osteopetrosis: novel bone modelling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases. J Bone Miner Res 23:1698\u20131707","journal-title":"J Bone Miner Res"},{"key":"3729_CR13","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/S0140-6736(01)07058-1","volume":"358","author":"FH Glorieux","year":"2001","unstructured":"Glorieux FH (2001) A disease of osteoblast. Lancet 358:S45","journal-title":"Lancet"},{"key":"3729_CR14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00003086-198109000-00004","volume":"159","author":"DO Sillence","year":"1981","unstructured":"Sillence DO (1981) Osteogenesis imperfecta: an expanding panorama of variants. Clin Orthop 159:11\u201325","journal-title":"Clin Orthop"},{"key":"3729_CR15","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jped.2014.05.003","volume":"90","author":"ER Valadares","year":"2014","unstructured":"Valadares ER, Carneiro TB, Santos PM, et al. (2014) What is new in genetics and osteogenesis imperfecta classification? J Pediatr 90:536\u2013541","journal-title":"J Pediatr"},{"key":"3729_CR16","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","volume":"363","author":"F Rauch","year":"2004","unstructured":"Rauch F, Glorieux FH (2004) Osteogenesis imperfecta. Lancet 363:1377\u20131385","journal-title":"Lancet"},{"issue":"Suppl 6","key":"3729_CR17","first-page":"1491","volume":"14","author":"FH Glorieux","year":"2001","unstructured":"Glorieux FH (2001) The use of bisphosphonates in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2001 14(Suppl 6):1491\u20131495","journal-title":"J Pediatr Endocrinol Metab 2001"},{"key":"3729_CR18","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","volume":"20","author":"D Gatti","year":"2005","unstructured":"Gatti D, Antoniazzi F, Prizzi R, et al. (2005) Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 20:758\u2013763","journal-title":"J Bone Miner Res"},{"key":"3729_CR19","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00228-012-1216-7","volume":"68","author":"N Maruotti","year":"2012","unstructured":"Maruotti N, Corrado A, Neve A, Cantatore FP (2012) Bisphosphonates effects on osteoblast. Eur J Clin Pharmacol 68:1013\u20131018","journal-title":"Eur J Clin Pharmacol"},{"key":"3729_CR20","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/pr.2014.20","volume":"75","author":"P D\u2019Eufemia","year":"2014","unstructured":"D\u2019Eufemia P, Finocchiaro R, Villani C, Zambrano A, Lodato V, Palombaro M, Properzi E, Celli M (2014) Serum brain-type creatine kinase increases in children with osteogenesis imperfecta during neridronate treatment. Pediatr Res 75:626\u2013630","journal-title":"Pediatr Res"},{"key":"3729_CR21","doi-asserted-by":"crossref","unstructured":"Tanaka M, Mori H, Kayasuga R, Kawabata K (2015) Induction of creatine kinase release from cultured osteoclasts via the pharmacological action aminobisphosphonates 3:4\u201359.","DOI":"10.1186\/s40064-015-0848-3"},{"key":"3729_CR22","first-page":"635","volume":"40","author":"G Schumann","year":"2002","unstructured":"Schumann G, Bonora R, Ceriotti F, Clerc-Renaud P, Ferrero CA, F\u00e9rard G, Franck PF, Gella FJ, et al. (2002) IFCC primary reference procedures for the measurements of catalytic activity concentration of enzymes at 37\u00b0C. Part 2: references procedures for the measurements of catalytic concentration of creatine kinase. Clin Chem Lab Med 40:635\u2013642","journal-title":"Clin Chem Lab Med"},{"key":"3729_CR23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0009-8981(68)90023-5","volume":"21","author":"TD Trainer","year":"1968","unstructured":"Trainer TD, Gruenig D (1968) A rapid method for the analysis of creatine phosphokinase isoenzymes. Clin Chim Acta 21:151\u2013154","journal-title":"Clin Chim Acta"},{"key":"3729_CR24","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1210\/jc.2011-1111","volume":"96","author":"BS Zemel","year":"2011","unstructured":"Zemel BS, Kalkwarf HJ, Gilsanz V, et al. (2011) Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: results of the bone mineral density in childhood study. J Clin Endocrinol Metab 96:3160\u20133169","journal-title":"J Clin Endocrinol Metab"},{"key":"3729_CR25","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","volume":"19","author":"RG Russell","year":"2008","unstructured":"Russell RG, Watts NB, Ebetino FH, et al. (2008) Mechanism of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733\u2013759","journal-title":"Osteoporos Int"},{"key":"3729_CR26","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1002\/art.30646","volume":"63","author":"T Matsumoto","year":"2011","unstructured":"Matsumoto T, Nagase Y, Iwasawa M, Yasui T, Masuda H, Kadono Y, Nakamuratetsuro Y, et al. (2011) Distinguishing the proapoptotic and antiresorptive function of riseidronate in murine osteoclast. Arthritis & Rheumatism 63:3908\u20133917","journal-title":"Arthritis & Rheumatism"}],"updated-by":[{"DOI":"10.1007\/s00198-016-3815-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,10,31]],"date-time":"2016-10-31T00:00:00Z","timestamp":1477872000000}}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-016-3729-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-016-3729-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-016-3729-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-016-3729-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:47:04Z","timestamp":1657154824000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-016-3729-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,25]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["3729"],"URL":"https:\/\/doi.org\/10.1007\/s00198-016-3729-x","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,25]]}}}